Ribavirin plus either peginterferon α-2a or peginterferon α-2b for patients with chronic HCV infection? Commentary

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 5, Issue 7, 2008, Pages 362-363

  Herrmann, Eva ^a   Zeuzem, Stefan ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

AREA UNDER THE CURVE; BLOOD ANALYSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VIROLOGY;

EID: 47249110211     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1155     Document Type: Short Survey

References (6)

1. Wohnsland A et al. (2007) Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 20 23-38
2. Fried MW et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982
3. Mihm U et al. (2006) Predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 23: 1043-1054
4. Schering-Plough reports top-line results of the IDEAL study [http://www.schering-plough.com/schering_enough/news/ release.jsp?releaseID=1096126] (accessed online 03 April 2008)
5. Berg T et al. (2006) Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130: 1086-1097
6. Harrison SA (2007) Small molecule and novel treatments for chronic hepatitis C virus infection. Am J Gastroenterol 102: 2332-2338